PEDIATRICS Vol. 119 No. 1 January 2007, pp. 165-170 (doi:10.1542/peds.2006-2901)

This Article Full Text Full Text (PDF) Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

POLICY STATEMENT

Cord Blood Banking for Potential Future Transplantation

In recent years, umbilical cord blood, which contains a rich source of hematopoietic stem and progenitor cells, has been used successfully as an alternative allogeneic donor source to treat a variety of pediatric genetic, hematologic, immunologic, and oncologic disorders. Because there is diminished risk of graft-versus-host disease after transplantation of cord stem cells using matched related donors, the use of less-than-completely matched HLA cord blood stem cells may incur less risk of graft-versus-host disease than mismatched cells from either a related or unrelated "walking" donor, although this remains to be proven. Gene-therapy research involving modification of autologous cord blood stem cells for the treatment of childhood genetic disorders, although experimental at the present time, may prove to be of value. These scientific advances have resulted in the establishment of not-for-profit and for-profit cord blood–banking programs for allogeneic and autologous cord blood transplantation. Many issues confront institutions that wish to establish or participate in such programs. Parents often seek information from their physicians about this new biotechnology option. This document is intended to provide information to guide physicians in responding to parents’ questions about cord blood donation and banking and the types and quality of cord blood banks. Provided also are recommendations about appropriate ethical and operational standards, including informed consent policies, financial disclosures, and conflict-of-interest policies for physicians, institutions, and organizations that operate or have a relationship with cord blood–banking programs.

Key Words: cord blood • stem cells • hematology • oncology

Abbreviations: FACT—Foundation for the Accreditation of Cellular Therapy • FDA—US Food and Drug Administration

This article has been cited by other articles:

				N. M Fisk and R. Atun Public-private partnership in cord blood banking BMJ, March 22, 2008; 336(7645): 642 - 644. [Full Text] [PDF]

				N. S. Fox, F. A. Chervenak, and L. B. McCullough Ethical Considerations in Umbilical Cord Blood Banking Obstet. Gynecol., January 1, 2008; 111(1): 178 - 182. [Abstract] [Full Text] [PDF]

				J. Smythe, S. Armitage, D. McDonald, D. Pamphilon, M. Guttridge, J. Brown, A. Green, C. Brown, R. M. Warwick, A. Lankester, et al. Directed Sibling Cord Blood Banking for Transplantation: The 10-Year Experience in the National Blood Service in England Stem Cells, August 1, 2007; 25(8): 2087 - 2093. [Abstract] [Full Text] [PDF]

				L. O'Keefe Great expectations: When should parents consider banking a newborn's cord blood? AAP News, January 1, 2007; 28(1): 17 - 17. [Full Text]